Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer

Cholangiocarcinoma Clinical Trial

Official title:

Phase 1 In-vivo Study of KSP/QRH Heptapeptide Dimer for Detection of Biliary Intra-epithelial Neoplasia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04304781
• Other study ID #: HUM00173620
• Status: Terminated
• Phase: Phase 1
• Start date: September 22, 2020
• Est. completion date: December 17, 2021

Study information

• Verified date: November 2022
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall aim of this feasibility study is to develop new technologies for improved detection of cholangiocarcinoma using the SFE-based molecular-imaging mini-cholangioscope (MC) system. This study will combine the use of a fluorescent-labeled peptide dimer that binds specifically to know biomarkers of cholangiocarcinoma for use as a novel imaging agent to guide endoscopic biopsies. This Phase 1B study will be used to provide early evidence of efficacy for the topical application of a peptide dimer that binds to molecular targets that are specific for biliary intra-epithelial neoplasia. A dimer is needed because cancer in the biliary tract is genetically heterogeneous. QRH binds specifically to Epidermal Growth Factor Receptor (EGFR), and KSP binds specifically to Human Epithelial Growth Factor Receptor (HER2). The study will look at peptide binding in subjects having a medical condition requiring an ERCP to diagnose a potential biliary disorder. The Phase 1A first-in-human studies of safety with topical administration by ingestion of KSP/QRH dimer (HUM00141420) has been completed.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: December 17, 2021
• Est. primary completion date: December 17, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

Subject meets all of the following criteria:

• Scheduled for an outpatient ERCP to diagnose a potential biliary disorder (such as an indeterminate biliary stricture)

• Subject is medically cleared for the procedure (e.g. washout for anticoagulants, co-morbidities)

• Age 18 to 100 years

• Willing and able to sign informed consent

Exclusion Criteria:

• Subjects with known allergy or negative reaction to any components of the study drug (list these)

• Subjects on active chemotherapy or radiation treatment

• Pregnant or trying to conceive

• Anything that, in the opinion of the investigator, would place the individual at increased risk or preclude the individual's full compliance with or completion of the study

Related Conditions & MeSH terms

• Cholangiocarcinoma

Intervention

Drug:
• KSP/QRH dimer
Peptide 919288G, Lot No. 17081402, Molecular Weight 3577.0, =95% purity. Stored at <20°C. Dark green, lyophilized powder in single-use amber vials.

Locations

Country	Name	City	State
United States	Michigan Medicine	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Danielle Kim Turgeon

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Contrast in Cell Fluorescence	The fluorescence intensity will be measured by the target/background (T/B) ratio from suspicious regions of bile duct where the fluorescent-labeled peptide is administered. The intensity of the fluorescence of the abnormal tissue compared to the background tissue intensity will be analyzed using statistical analysis for significance comparing the tissue groups' mean T/B ratios.	During and immediately after procedure, generally no more than 2 hours